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Transferability of ETP-based 
APC resistance assay on the ST 
Genesia system 
BACKGROUND
• Regulatory bodies recommend assessing the ETP-based
APC resistance assay during the development of steroid
contraceptives.
• In 2019, this assay was validated on the Calibrated
Automated Thrombogram using commercially available
reagents to ensure batch-to-batch traceability, and
reproducibility of the method over time.
AIMS
To implement the ETP-based APC resistance assay on the
automated ST Genesia system using reagent STG-
ThromboScreen -TM (TS –TM) with exogenous APC added.
METHODS
• Determination of APC concentration leading to 90%±2.5% of
ETP inhibition of a healthy pooled plasma, using 2 different
batches of TS –TM.
• Intra- (N=5) and inter-run (N=10) reproducibility of ETP
inhibition assessed on 3 lyophilized samples.
• Reference ranges defined based on 56 plasma samples.
• Sensitivity assessed on 36 females using combined oral
contraceptives (COCs).
RESULTS
• [APC]mU/mL defined at 652 mU/mL [IC95%: 534-805 mU/mL]
on both batches of TS – TM (Figure 1).
• ETP inhibition SD <2.0% for intra-run and <3.5% for inter-
run reproducibility (Table 1).
• Mean ETP inhibition % [IC95] over 56 samples equaled
89.5% [87.3%-91.6%] (Figure 2).
• Significantly lesser response to APC of women using COC
compared to healthy individuals (Figure 2).
SUMMARY/CONCLUSION
This study is the first reporting the transferability of the ETP-
based APC resistance assay on the ST Genesia system. Data
revealed excellent precision (within- and between-run
reproducibility) and provided an appropriate sensitivity
depending on the hormonal status of women. Confirmation of
promising results on thrombogenicity identification for all COC
users is still needed before this test can be commercially
available.
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Figure 1: Inhibition percentages of
ETP of a healthy pooled plasma
(HPP) at various concentrations of
APC (mU/mL), using two batches of
TS –TM. The blue continuous line
represents the mean non-linear
regression obtained with both batches
of TS –TM. The horizontal grey dotted
lines represent the maximal tolerated
inhibition percentage of HPP,
corresponding to 90% ±2.5% . The red
vertical lines represent the APC
concentration [IC95] leading to 90% of
inhibition of the ETP and corresponds























































L R2 = 0,9982
90±2.5%
Tested plasma 






TS 73.5% ± 1.0% 74.5% ± 3.5%
STG-QualiTest
Norm TS 38.5% ± 2.0% 37.7% ± 3.5%
STG-QualiTest
High TS 8.7% ± 1.7% 10.1% ± 1.4%
Table 1: Intra-run and inter-run
reproducibility of ETP inhibition of the
commercial reference plasma and two
quality controls.
Intra-run reproducibility was based on
5 measurements of each tested
plasma and the inter-run
reproducibility was based on 10 runs
measuring each tested plasma.
Results are expressed as mean
inhibition % ± standard deviation (SD)
Figure 2: Inhibition % of ETP of 
individuals from each subgroup, i.e., 
healthy individuals (N=56), 
women using COC containing:  
- ethinylestradiol (EE) + 
levonorgestrel(LNG) (N=18);
- EE + desogestrel (DSG)/ 
gestodene(GSD) (N=12); 
- EE + drospirenone (DRSP)/ 
cyproterone acetate (CPA)/ 
dienogest (DNG) (N=6). 
Individuals values and mean ETP
inhibition ± SD for each subgroup are
represented. Differences between
subgroups were assessed by a Holm-
Sidak’s multiple comparison test. P-
value are characterized as following:
ns = P>0.05; * = P≤0.05; ** = P≤0.01











































































89 % ± 8%
